Classic psychedelics like psilocybin, LSD, and DMT work primarily by activating a specific serotonin receptor in the brain called 5-HT2A. This single interaction triggers a cascade of effects: disrupted sensory filtering, loosened communication between brain networks, and the growth of new neural connections. The result is the characteristic combination of altered perception, dissolved sense of self, and emotional intensity that defines a psychedelic experience.
The Serotonin Receptor That Starts It All
Your brain has at least 14 types of serotonin receptors, but classic psychedelics exert their primary effects through just one: the 5-HT2A receptor. When a psychedelic molecule binds to this receptor, it activates a specific signaling pathway inside the cell. Research has pinpointed this to a pathway called Gq-PLC signaling, and a threshold level of activation along this pathway is required to produce psychedelic effects. This explains why some compounds that also bind to 5-HT2A receptors, like lisuride, don’t produce a trip. They activate the receptor but don’t push the Gq pathway hard enough to cross that threshold.
Different psychedelics bind to 5-HT2A with different strengths. LSD binds with significantly higher affinity than psilocin (the active form of psilocybin) or DMT, which is part of why LSD is active at microgram doses while psilocybin requires milligrams and DMT requires tens of milligrams. LSD also lodges into the receptor in a way that keeps it activated for much longer, contributing to trips that can last 8 to 12 hours compared to psilocybin’s 4 to 6 hours.
How the Brain’s Sensory Filter Breaks Down
Under normal conditions, a region deep in the brain called the thalamus acts as a gatekeeper. It filters the enormous flood of sensory information coming from your eyes, ears, and body before passing a curated version up to the cortex for conscious processing. Think of it as a bouncer deciding what gets through to your awareness and what stays in the background.
Psychedelics disrupt this filter. By stimulating 5-HT2A receptors on neurons within the thalamic circuit, they loosen the gate and allow sensory information to reach the cortex in a less controlled way. Neuroimaging studies show increased connectivity between the thalamus and sensory areas of the cortex during a psychedelic state, which correlates with the intensity of visual and auditory distortions people report. The brain is essentially receiving more raw sensory data than it normally would, and the cortex struggles to organize it using its usual patterns. That’s when colors intensify, surfaces ripple, sounds take on new textures, and the boundaries between senses can blur.
Your Brain’s Default Wiring Gets Reshuffled
One of the most consistent findings in psychedelic neuroimaging is what happens to the Default Mode Network, a group of interconnected brain regions that are most active when you’re not focused on the outside world. The DMN handles self-reflection, mind-wandering, autobiographical memory, and your ongoing sense of being “you.” It’s the neural basis of your inner narrator.
Psychedelics reliably decrease connectivity within the DMN while simultaneously increasing connectivity between brain networks that don’t normally talk to each other. Under psilocybin, researchers have documented significant changes in nearly 700 out of roughly 35,000 possible brain connections. Key hubs of the DMN, particularly in the medial prefrontal cortex and the posterior cingulate cortex, decouple from each other. This pattern appears consistently across psilocybin, LSD, and ayahuasca.
The subjective result of this rewiring is what people describe as ego dissolution: the feeling that the boundary between self and world is thinning or disappearing. Electroencephalography studies show that psychedelics desynchronize a type of brainwave called alpha power, which is closely linked to DMN activity. The working hypothesis is that reducing this synchronized activity produces a mind that is less constrained by habitual self-referential thinking, more flexible, and more open to new patterns of thought. In depressed patients, decreased DMN integration has been observed up to three weeks after a single psilocybin dose.
Growing New Brain Connections
Beyond the acute experience, psychedelics promote physical changes in neurons. They encourage the growth of dendritic spines, the tiny protrusions on brain cells where connections with other neurons form. This process, called neuroplasticity, is central to how the brain learns and adapts.
There appear to be two distinct mechanisms driving this. One involves the 5-HT2A receptor: when psychedelic compounds cross into the interior of a neuron and bind to receptors inside the cell, they trigger spine growth. A compound’s ability to penetrate the cell membrane, rather than just activating receptors on the surface, predicts how effectively it promotes new connections.
The second mechanism is even more striking. LSD and psilocin directly bind to TrkB, the receptor for a key growth-promoting protein called BDNF (brain-derived neurotrophic factor). They bind to TrkB with affinities roughly 1,000 times higher than conventional antidepressants like fluoxetine. This TrkB binding promotes the brain’s own neurotrophic signaling and operates independently of the 5-HT2A receptor. In other words, the plasticity-promoting effects of psychedelics and their hallucinogenic effects appear to run through separate biological pathways. The hallucinations depend on 5-HT2A activation; the neural rewiring depends largely on TrkB.
This distinction is significant for mental health applications. It suggests that the long-lasting improvements in depression that follow a psychedelic session aren’t just a memory of a profound experience. They reflect actual structural changes in neural circuitry, with new connections forming in regions that may have been underconnected.
How MDMA and Ketamine Differ
MDMA and ketamine are often grouped with classic psychedelics, but they work through fundamentally different mechanisms.
MDMA (ecstasy) is classified as an entactogen rather than a hallucinogen. Instead of directly activating 5-HT2A receptors, it floods the brain with serotonin by forcing serotonin transporters to work in reverse. Blocking serotonin reuptake with an SSRI nearly eliminates MDMA’s psychological effects, confirming that the serotonin surge is the primary driver. MDMA activates emotional and limbic brain regions while quieting the amygdala, the brain’s threat-detection center. The result is heightened mood, increased feelings of closeness, and mild perceptual changes like intensified colors, but virtually no hallucinations. Blocking 5-HT2A receptors reduces MDMA’s mild visual effects but leaves the emotional experience mostly intact.
Ketamine takes yet another route. It blocks NMDA receptors, a type of glutamate receptor involved in excitatory signaling throughout the brain. Like classic psychedelics, ketamine disrupts thalamic filtering, but it does so by interfering with glutamate transmission along the pathways that connect the cortex to the thalamus, rather than through serotonin. The dissociative, dreamlike quality of a ketamine experience reflects this different mechanism of sensory disruption.
What Happens in the Body
Classic psychedelics produce measurable cardiovascular changes. Heart rate and blood pressure rise in a dose-dependent way across psilocybin, LSD, and DMT. These increases are transient and generally don’t require medical intervention. With LSD, doses above 25 micrograms produce significant, temporary blood pressure and heart rate increases, and in one pooled analysis, 48% of LSD doses tested pushed systolic blood pressure above 140 mmHg. Psilocybin causes similar effects, though only at high doses (above roughly 40 mg) have researchers observed changes in heart rhythm significant enough to warrant monitoring. Ayahuasca and DMT produce comparable short-lived spikes in heart rate and blood pressure.
Tolerance Builds Fast and Fades Within Days
Psychedelics produce rapid tolerance. After a single dose, 5-HT2A receptors on cortical neurons begin to internalize, pulling back from the cell surface and reducing the brain’s sensitivity to further stimulation. This downregulation is detectable within 24 hours. The internalization process for psychedelic compounds is notably slower than for serotonin itself: receptors take about 7.5 hours to recycle after psychedelic activation, compared to roughly 2.5 hours after activation by the body’s own serotonin.
This tolerance is cross-reactive, meaning taking LSD will reduce the effects of psilocybin taken shortly afterward, and vice versa, because both compounds act at the same receptor. Most users find that full sensitivity returns within about 7 to 14 days, as the receptor population on neuron surfaces replenishes. This built-in tolerance mechanism is one reason psychedelics have low potential for compulsive daily use, unlike substances that act on dopamine reward pathways.
Timeline of a Psychedelic Experience
Psilocybin is converted in the body to its active form, psilocin, which reaches peak blood levels about 2 hours after an oral dose. Effects typically begin within 30 to 60 minutes, build to a peak around 1.5 to 2.5 hours, and resolve within 4 to 6 hours total. The drug follows predictable, dose-proportional behavior, meaning doubling the dose roughly doubles the blood concentration of psilocin.
LSD lasts considerably longer, with effects persisting 8 to 12 hours. Mescaline (found in peyote and San Pedro cacti) is longer still. DMT, when smoked or injected, produces an intense but brief experience lasting only 15 to 30 minutes. When DMT is consumed as ayahuasca, a plant-based brew containing a compound that prevents DMT’s rapid breakdown in the gut, the experience extends to 3 to 5 hours. Despite these differences in timing and dose, controlled comparisons have found no qualitative difference in the type of altered consciousness produced by psilocybin, LSD, and mescaline at equivalent doses. The core experience, a temporary loosening of the brain’s usual filtering and self-referential processing, is the same across classic psychedelics. The route in differs; the destination does not.